DOD Biotech Public : Report use of proceeds from initial public offering of ordinary shares
July 18, 2022 at 01:04 pm
Share
No. DOD-E067/2565
July 18th, 2022
Subject: Use of proceeds from initial public offering of ordinary shares
To: President
The Stock Exchange of Thailand
DOD Biotech Public Company Limited ("the Company") made an initial public offering ("IPO") of ordinary shares during June 12-14, 2018 in the amount of 110,000,000 shares each of Baht0.50 par value at the offering price of Baht 9.30 per share, totaling Baht 1,023,000,000. After deduction of offering expenses, the proceeds from the IPO amount to Baht 987,240,850.
The company would link to report the use of capital increase from the IPO for January 1, 2022 to June 30, 2022 as follows:
Purposes of use
Amount
Resolution of
Resolution of
Amount
Accumulated
Balance
(Unit: Baht million)
earmarked
the Board of
the 2019
used during
amount used
remaining
Directors No.
Annual
period
(Jun 15, 2018-
(Jun 30,
8/2018 on
General
(Jan 1, 2022-
Jun 30, 2022)
2022)
19/12/2018
Meeting on
Jun 30, 2022)
30/04/2019
1.
Investment in raw
100.00
100.00
260.00
29.02
241.32
18.68
material extraction plant
and world-class research
laboratory
2. Development of the
200.00
200.00
-
-
-
-
Company's new brand
3. Repayment of loans to
50.00
50.00
46.89
-
46.89
-
financial institutions
4. Working capital for
637.34
368.34
221.45
-
221.45
-
business operation
5. Expansion of production
-
120.90
120.90
-
120.90
-
capacity for dietary
supplement products,
introduction of new
product packages, and
warehouse building
(related to existing
business as disclosed in
the Registration Statement
for offer for sale of
securities and draft
prospectus)
Page 1 | 2
Purposes of use
Amount
Resolution of
Resolution of
Amount
Accumulated
Balance
(Unit: Baht million)
earmarked
the Board of
the 2019
used during
amount used
remaining
Directors No.
Annual
period
(Jun 15, 2018-
(Jun 30,
8/2018 on
General
(Jan 1, 2022-
Jun 30, 2022)
2022)
19/12/2018
Meeting on
Jun 30, 2022)
30/04/2019
6. Lending to a subsidiary
-
148.00
148.00
-
148.00
-
for investment and
expansion of contracted
manufacturing of
cosmetics- PCCA
Laboratory Co., Ltd. (new
business)
7. Use to repay loans from
-
-
150.00
-
150.00
-
financial institution Which
is intended for investment
in PCCA (New Business)
8.Use investment in
-
-
40.00
-
40.00
-
subsidiaries that operate
direct sale business (New
business)
Total
987.24
987.24
987.24
29.02
968.56
18.68
Please be informed accordingly.
Yours sincerely,
Miss Suwarin Konthong
Director
Page 2 | 2
Attachments
Original Link
Original Document
Permalink
Disclaimer
DOD Biotech pcl published this content on 18 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 July 2022 12:03:01 UTC.
DOD Biotech Public Company Limited is a Thailand-based company, which is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The Companyâs segments include supplementary business, manufacturing extraction business, and others. Its products categories include dietary supplements; health products, such as health supplements, and own-branded products under brand Dieto, which is a protein food supplement, that helps to maintain shape, as well as it helps to reduce the accumulation of excess fat nervous system. It offers tablet products, such as capsules and flower tablets. The Company provides drinking powder, such as Fiber Detox, which is a product with high fiber content, which helps in the digestive system. Its subsidiaries include DOD Healthy Life Co., Ltd., Siam Herbal Tech Co., Ltd., AK DOD Co., Ltd., A Metaverse Co., Ltd., and DOD Sale power Co., Ltd.
DOD BIOTECH 
